CAS 1195768-06-9
:Dabrafenib mesylate
Description:
Dabrafenib mesylate is a targeted anticancer medication primarily used in the treatment of certain types of melanoma, particularly those with BRAF V600E mutations. It is a small molecule inhibitor that selectively targets and inhibits the BRAF protein, which is involved in cell signaling pathways that regulate cell growth and division. The mesylate salt form enhances its solubility and stability, facilitating its use in clinical settings. Dabrafenib mesylate is typically administered orally and is often used in combination with other therapies, such as trametinib, to improve treatment efficacy. The compound is characterized by its ability to inhibit tumor growth and is associated with various side effects, including fever, fatigue, and skin reactions. Its pharmacokinetics indicate a relatively rapid absorption and a half-life that supports once or twice daily dosing. As with many targeted therapies, monitoring for adverse effects and therapeutic response is crucial during treatment.
Formula:C24H24F3N5O5S3
InChI:InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
InChI key:InChIKey=YKGMKSIHIVVYKY-UHFFFAOYSA-N
SMILES:FC1=C(C2=C(SC(C(C)(C)C)=N2)C3=NC(N)=NC=C3)C=CC=C1NS(=O)(=O)C4=C(F)C=CC=C4F.S(C)(=O)(=O)O
Synonyms:- GSK 2118436 methanesulfonate salt
- GSK 2118436B
- Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1)
- N-[3-[5-(2-Aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide methanesulfonic acid
- Dabrafenib mesylate
- Dabrafenib Mesylate (GSK2118436 Mesylate
- DABRAFENIB MESYLATE (GSK 2118436B);GSK-2118436 MESYLATE;GSK2118436 MESYLATE;GSK 2118436 MESYLATE
- N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonic acid
- GSK2118436 Mesylate
- Dabrafenib, Methanesulfonate Salt
- N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzen
- Dabrfenib Mesylate
- GSK 2118436 Mesylate
- Dabrafenib Mesylate (API)
- Dapafini mesylate
- N-(3-(5-(2-Aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide methanesulfonate
- N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide methanesulfonate
- GSK-2118436 Mesylate
- GSK2118436 Ms salt, Dabrafenib Ms salt, GSK2118436A Ms salt
- abrafenibmesylate
- Dabrafenib Mesylate(GSK-2118436B)
- Dabrafenib Mesylate (GSK-2118436)
- Debrafenib Mesylate (API)
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, methanesulfonate (1:1)
CAS:Formula:C24H24F3N5O5S3Purity:99%Color and Shape:SolidMolecular weight:615.6681Dabrafenib Mesylate
CAS:<p>Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).</p>Formula:C24H24F3N5O5S3Purity:99.45% - 99.82%Color and Shape:SolidMolecular weight:615.67Dabrafenib Mesylate
CAS:Controlled Product<p>Stability Hygroscopic<br>Applications Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.<br>References Hauschild, A., et al.: Lancet, 380, 358 (2012); Falchook, G.S., et al.: Lancet, 379, 1893 (2012); Ascierto, P.A., et al.: J. Clin. Oncol., 31, 3205 (2013)<br></p>Formula:C23H20F3N5O2S2·CH4O3SColor and Shape:WhiteMolecular weight:615.67Dabrafenib mesylate
CAS:<p>Inhibitor of B-Raf kinase mutant</p>Formula:C23H20F3N5O2S2·CH4O3SPurity:Min. 95%Color and Shape:White/Off-White SolidMolecular weight:615.67






